MYL

Mylan N.V.

Healthcare


Presented:10/30/2017
Price:$38.24
Cap:$20.53B
Current Price:$11.84
Cap:$14.13B

Presented

Date10/30/2017
Price$38.24
Market Cap$20.53B
Ent Value$34.87B
P/E Ratio31.34x
Book Value$23.94
Div Yield0%
Shares O/S537.00M
Ave Daily Vol7,285,386
Short Int4.74%

Current

Price$11.84
Market Cap$14.13B
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.

Publicly traded companies mentioned herein: Amgen Inc (AMGN), Mylan PLC (MYL), Sanofi (SNY), Teva Pharmaceutical Industries Ltd (TEVA)

Highlights

Despite Mylan’s recent troubles, including missteps by management and overall industry pressure, the presenter is long MYL stock and believes further downside risk could be limited. With the stock trading at $38, the forward P/E multiple is just 7x. In his opinion, this is “probably unfair”, as it looks like the catalyst path could favor Mylan going forward. Overall, expectations may be too conservative. Both Advair and Lantus could see positive news flow over the next 12 months, and if the presenter's model is accurate, Mylan is likely to earn ~$6 per share in 2018 (versus the Street at $5.30). If the multiple expands from 7x to 9-10x over the next 12 months, patient investors could see 40% upside, or better.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.